source
- Biopharma looks beyond China to five alternative overseas markets amid rising geopolitical tensionsGeopolitical tensions between the United States and China are prompting biopharma companies to look beyond the Chinese market for growth. China remains the leading destination, with licensing deal…
- Biotech crossover rounds projected to exceed $4.2 billion in 2026, supporting IPO pipelinePitchBook forecasts that biotech crossover rounds could surpass $4.22 billion across roughly 28 rounds in 2026. The surge follows a market bottom after COVID and a rise in investor confidence, wit…